Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Samuel Goldsmit

Neurological Surgery Miami, FL Medical Doctor

NPI 1518221266 CMS profile 295883

4302 Alton Rd Ste 830, Ste 245, Miami, FL 33140

Open in the dashboard

General payments

$519,397

946 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Samuel Goldsmit of Miami, FL is reported in the CMS Open Payments database as having received $519,397 across 946 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $90,883 183
2024 General $132,228 201
2023 General $139,997 177
2022 General $109,276 185
2021 General $34,717 86
2020 General $2,848 35
2019 General $9,448 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samuel Goldsmit
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Samuel Goldsmit were reported at $90,883. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Samuel Goldsmit Neurological Surgery median Middle half National median
2019 $9,448 $582 $138–$3,006 $163
2020 $2,848 $294 $76–$2,174 $114
2021 $34,717 $387 $105–$2,432 $132
2022 $109,276 $542 $139–$2,989 $149
2023 $139,997 $534 $145–$2,697 $160
2024 $132,228 $574 $155–$3,046 $164
2025 $90,883 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $452,732 665 payments
  2. Alphatec Spine, Inc $27,251 25 payments
  3. Highridge Medical LLC $13,076 16 payments
  4. Medtronic USA, Inc. $6,990 56 payments
  5. NuVasive, Inc. $4,241 51 payments
  6. Hyhte Holdings Inc. $3,008 1 payment
  7. Stryker Corporation $2,792 37 payments
  8. Globus Medical, Inc. $2,104 18 payments
  9. Orthofix Medical, Inc. $1,833 16 payments
  10. Carlsmed, Inc. $1,477 14 payments
  11. Other $3,893 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $353,483 53 payments
  2. Travel and Lodging $72,474 355 payments
  3. Consulting Fee $53,632 12 payments
  4. Food and Beverage $36,136 523 payments
  5. Royalty or License $3,008 1 payment
  6. Education $664 2 payments
Products named General payments · program years 2019–2025
  1. CLYDESDALE PTC SPINAL SYSTEM $172,739 178 payments
  2. STEALTHSTATION S8 PLATFORM $45,319 65 payments
  3. PIVOX Oblique Lateral Spinal System $40,611 60 payments
  4. CD HORIZON SPINAL SYSTEM $35,863 66 payments
  5. O-ARM $34,688 21 payments
  6. CATALYFT PL EXPANDABLE INTERBODY SYSTEM $25,266 46 payments
  7. MAZOR X SYSTEM $19,435 30 payments
  8. CLYDESDALE $19,324 15 payments
  9. Other - Miscellaneous $13,721 14 payments
  10. Vital $12,443 13 payments
  11. Other $68,356 387 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

42

Median for Neurosurgery: 83

Drug cost

$766

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methocarbamol Generic 42 $766

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$200,190

Medicare's payments for the services billed

Medicare patients

221

Average age 76

Services billed

632

108 women, 113 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 70%
Ischemic heart disease 43%
Diabetes 35%
Depression 33%
Chronic kidney disease 29%
Osteoporosis 25%
Cancer 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

946 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record